AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20668372
Drug: 150 ml
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml black tea extract (BTE) daily for weeks 1-4 (increasing to 600 ml by week 4)
Trial: 20668372
Drug: 600 ml
RxNorm normalized name: urinary bag 600 mL-10" MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 ml black tea extract (BTE) daily
Trial: 20668372
Drug: 150 ml
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml black tea extract (BTE) daily (control group)
Trial: 7587908
Drug: Multiple injection
RxNorm normalized name: sodium acetate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple injection regimen of insulin therapy (Group II, n = 9)
Trial: 19797937
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg controlled-release oxycodone
Trial: 10898540
Drug: Docetaxel 60
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 60 mg/m2 followed by CPT‐11 190 mg/m2 on day 1, repeated every 3 weeks
Trial: 8438659
Drug: Twice-weekly exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly exercise
Trial: 3940518
Drug: Oral meclizine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral meclizine
Trial: 28468653
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin (81 mg) daily administration, initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA
Trial: 28468653
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin (81 mg)
Trial: 22751026
Drug: Analgesics after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics after ED care
Trial: 1598953
Drug: cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cromolyn sodium 4% ophthalmic solution
Trial: 4044294
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg riboflavin supplementation
Trial: 4044294
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg riboflavin supplementation
Trial: 4044294
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg riboflavin supplementation
Trial: 4044294
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg riboflavin load
Trial: 2493400
Drug: Danazol (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (800 mg per day)
Trial: 2963213
Drug: Nafarelin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin (both doses) and Danazol
Trial: 26951845
Drug: PEITC (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEITC (10 mg in 1 mL of olive oil, 4 times per day)
Trial: 27916036
Drug: Patient Controlled
RxNorm normalized name: PATIENT CONTROLLED ANALGESIA VIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient Controlled Intravenous Analgesia (PCIA)
Trial: 15753744
Drug: Decision support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision support on (smart infusion pumps with integrated decision support software)
Trial: 15246599
Drug: 9-valent pneumococcal
RxNorm normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-valent pneumococcal conjugate vaccine
Trial: 10452624
Drug: Combined vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined vaccine
Trial: 31314753
Drug: Weight-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based dosing for diethylcarbamazine (DEC; 6 mg/kg) and ivermectin (IVM; 200 ug/kg)
Trial: 31314753
Drug: New dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New dosing pole with a 6-tablet maximum for both DEC and IVM
Trial: 20973770
Drug: Imiquimod cream
RxNorm normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod cream (5%)
Trial: 30400777
Drug: Podophyllotoxin cream
RxNorm normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Podophyllotoxin cream (0.15%)
Trial: 19958541
Drug: Verum acupuncture
RxNorm normalized name: Cinnamomum verum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verum acupuncture (treatment group)
Trial: 20394651
Drug: Azacitidine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azacitidine (75 mg/m2/day SC for 7 days every 28 days)
Trial: 20394651
Drug: Conventional care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional care regimens (CCR) including low-dose ara-C, BSC, or intensive chemotherapy
Trial: 18759641
Drug: Risperidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (mean dose = 3.4 mg)
Trial: 18759641
Drug: Olanzapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (mean dose = 14.0 mg)
Trial: 18759641
Drug: Quetiapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (mean dose = 611 mg)
Trial: 8941061
Drug: Four-pellet system
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-pellet system containing 174 mg NET
Trial: 8941061
Drug: Five-pellet system
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-pellet system containing 266.5 mg NET
Trial: 29703470
Drug: Apixaban 2.5
RxNorm normalized name: apixaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 2.5 mg BID
Trial: 12779109
Drug: Ketamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (10 mg/kg) + Promethazine (1.1 mg/kg)
Trial: 12779109
Drug: Ketamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (10 mg/kg)
Trial: 7502276
Drug: Ketorolac infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac infusion
Trial: 8010474
Drug: Ketorolac infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac infusion and bolus
Trial: 28316664
Drug: Neurofeedback therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurofeedback therapy (20 sessions of 40 minutes each, 3 sessions per week)
Trial: 10778884
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg DHEA administered orally at 0700 hours
Trial: 8793448
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nedocromil sodium
Trial: 1333423
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day itraconazole for 15 days
Trial: 1333423
Drug: 500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day griseofulvin for 15 days
Trial: 30991399
Drug: OZOILE cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OZOILE cream (ozonides with vitamin E acetate)
Trial: 30991399
Drug: 0.1% mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% mometasone furoate (topical corticosteroid)
Trial: 22531061
Drug: Focused-image ultrasonography
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Focused-image ultrasonography with more treatment lines and higher joule energy at dual depths
Trial: 18600434
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g PEG 400
Trial: 18600434
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g PEG 400
Trial: 18600434
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g PEG 400
Trial: 18600434
Drug: 1.25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 g PEG 400
Trial: 10930561
Drug: Caffeine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (100 mg)
Trial: 9864074
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg daily for up to 12 weeks (short-term therapy)
Trial: 9864074
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 52 weeks (long-term therapy)
Trial: 9864074
Drug: Fluoxetine for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine for 52 weeks (long-term therapy)
Trial: 2094589
Drug: Peptide Plasmodium
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide Plasmodium falciparum sporozoite vaccine conjugated to tetanus toxoid ((NANP)3‐TT) plus placebo (group 1)
Trial: 10917405
Drug: Codeine 120
RxNorm normalized name: TY-PAP with Codeine 120mg-12mg/5ml Elixir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine 120 mg
Trial: 788993
Drug: Codeine 60
RxNorm normalized name: codeine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine 60 mg
Trial: 19753607
Drug: Trichosanthes kirilowii
RxNorm normalized name: TRICHOSANTHES KIRILOWII ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trichosanthes kirilowii (TK) seed kernels containing 3 g of punicic acid (PA) per day for 28 days
Trial: 12207145
Drug: Flupenthixol 5-15
RxNorm normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupenthixol 5-15 mg/day
Trial: 11148810
Drug: Timolol treatment
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol treatment
Trial: 2547409
Drug: Metered-dose inhaler
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered-dose inhaler (MDI)
Trial: 3826899
Drug: Metered-dose inhaler
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered-dose inhaler with holding chamber (MDI-HC)
Trial: 24468407
Drug: Prismatic adaptation
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prismatic adaptation (PA) with a leftward aftereffect administered outside the scanner.
Trial: 21911045
Drug: Fufangkushen colon-coated
RxNorm normalized name: Sus scrofa colon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fufangkushen colon-coated capsule (FCC)
Trial: 21911045
Drug: Huidi (HD,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huidi (HD, mesalazine enteric-coated tablets)
Trial: 19819724
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) 800 mg oral daily for 20 weeks
Trial: 16289802
Drug: Hypnotic suggestions
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic suggestions inducing negative emotions
Trial: 10973133
Drug: S. melongena
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. melongena infusion (N = 19)
Trial: 10973133
Drug: S. melongena
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. melongena infusion without dietary orientation (N = 38)
Trial: 21458651
Drug: Implant-assisted mandibular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-assisted mandibular dentures
Trial: 15333404
Drug: Rocuronium 10
RxNorm normalized name: rocuronium 10 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 10 mg/mL
Trial: 15333404
Drug: Rocuronium 1
RxNorm normalized name: rocuronium 10 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 1 mg/mL
Trial: 15333404
Drug: Rocuronium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.5 mg/mL
Trial: 10950032
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg four times daily
Trial: 8470632
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg four times daily
Trial: 3780291
Drug: Pinaverium bromide
RxNorm normalized name: pinaverium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinaverium bromide 100 mg twice daily for 3 days before and 100 mg 1 hour before examination
Trial: 27721231
Drug: Cold dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold dialysis solution at 35.5°C
Trial: 27721231
Drug: Conventional dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dialysis solution at 37°C
Trial: 22695364
Drug: Isoniazid (INH)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (INH) 10-20 mg·kg·d orally
Trial: 2196926
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1% hydrocortisone cream and 2% miconazole cream
Trial: 6101961
Drug: Pirbuterol 10
RxNorm normalized name: pirbuterol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirbuterol 10 mg four times daily
Trial: 6101961
Drug: Salbutamol 4
RxNorm normalized name: Salbutamol 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 4 mg four times daily
Trial: 22700717
Drug: Lipid-lowering treatment
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering treatment (LLT)
Trial: 19962941
Drug: Pramipexole (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (0.125 to 0.75 mg/day for 6 weeks)
Trial: 17377856
Drug: Direct autologous
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct autologous retransfusion of shed thoracic blood (350 ml)
Trial: 17377856
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (350 ml saline)
Trial: 16352934
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg of ramosetron (RAM) combined with 8 mg of dexamethasone (DEX)
Trial: 30099811
Drug: Losartan 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 5% ointment
Trial: 16036167
Drug: Ginger capsule
DrugBank: Ginger (DB10344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger capsule
Trial: 16036167
Drug: Bottle filled
RxNorm normalized name: bottlebrush pollen extract
DrugBank: Callistemon citrinus pollen (DB10943)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bottle filled with ginger capsules
Trial: 16036167
Drug: Bottle filled
RxNorm normalized name: bottlebrush pollen extract
DrugBank: Callistemon citrinus pollen (DB10943)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bottle filled with placebo capsules
Trial: 12203743
Drug: Further treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Further treatment to reduce risk
Trial: 12203743
Drug: Minor variations
RxNorm normalized name: Vinca minor extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minor variations in treatment protocol
Trial: 6803278
Drug: L-tryptophan (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (5 g)
Trial: 6803278
Drug: Pyridoxine (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine (125 mg three times daily with meals) and L-tryptophan (3 g at 10 PM)
Trial: 30735922
Drug: Antipsychotic switch
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic switch during the 8-week acute phase
Trial: 25058216
Drug: Erythropoietin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (500 IU/kg per dose)
Trial: 25058216
Drug: Hemoglobin transfusion
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin transfusion threshold of 10 g/dL
Trial: 25058216
Drug: Transfusion threshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion threshold of 10 g/dL
Trial: 19777213
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg BZP
Trial: 17580150
Drug: Sirolimus conversion
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus conversion treatment (RAPA)
Trial: 31567567
Drug: BDG-guided empiric
RxNorm normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDG-guided empiric antifungal treatment
Trial: 24229749
Drug: OROS methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS methylphenidate (72 mg/d)
Trial: 17688463
Drug: Oral atypical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral atypical antipsychotic (AAP)
Trial: 15507939
Drug: Single-dose parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Single-dose parecoxib sodium 40 mg
Trial: 15507939
Drug: Multiple-dose parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Multiple-dose parecoxib sodium 20 mg, 4 times daily
Trial: 15507939
Drug: Multiple-dose parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Multiple-dose parecoxib sodium 40 mg, twice daily
Trial: 31462203
Drug: Accelerated initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Accelerated initiation of renal replacement therapy
Trial: 28035867
Drug: SC golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: SC golimumab 50 mg (Group 2-SC)
Trial: 28035867
Drug: IV golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV golimumab 2 mg/kg (Group 2-IV)
Trial: 7955822
Drug: Caffeine-containing analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine-containing analgesic (APAP/ASA/CAF: 500 mg acetaminophen, 500 mg aspirin, 130 mg caffeine)
Trial: 3211484
Drug: 1.0 mg/ml
RxNorm normalized name: P.T.E.-4, 1 mcg-0.1 mg-0.025 mg-1.0 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/ml mitomycin eye drops
Trial: 3211484
Drug: 0.4 mg/ml
RxNorm normalized name: thymol 0.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/ml mitomycin eye drops
Trial: 27780692
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein diet combined with weight-loss cognitive behavioral therapy
Trial: 27780692
Drug: High carbohydrate
RxNorm normalized name: High carbohydrate food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High carbohydrate diet combined with weight-loss cognitive behavioral therapy
Trial: 21697075
Drug: 300 IU/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 IU/d from supplements
Trial: 21697075
Drug: a one-time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a one-time seasonal supplement of 13,700 IU
Trial: 18827019
Drug: 75 mg/day
RxNorm normalized name: Lyllana 0.075 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/day dehydroepiandrosterone (DHEA)
Trial: 18827019
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day dehydroepiandrosterone (DHEA)
Trial: 16821176
Drug: Intense activating
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intense activating group treatment (subgroup analysis)
Trial: 10695822
Drug: Soy formula
RxNorm normalized name: Nursoy Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy formula daily
Trial: 10695822
Drug: Therapeutic oral
RxNorm normalized name: multivitamin,therapeutic ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic oral iron treatment
Trial: 3002720
Drug: Ortho Vaginal
RxNorm normalized name: Ortho-Nesic
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ortho Vaginal Tablets (OVT)
Trial: 3002720
Drug: Emko Vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emko Vaginal Tablets (EVT)
Trial: 28816373
Drug: 80 mL
RxNorm normalized name: urinary bag 480 mL MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mL simethicone/Pronase solution plus 10 mL lidocaine hydrochloride mucilage (SP/LHM)
Trial: 28816373
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL lidocaine hydrochloride mucilage (LHM)
Trial: 21174129
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy (BT) sleep intervention
Trial: 18349431
Drug: Subjects randomized
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to estimate the probability of treatment success after learning their diagnosis (after group)
Trial: 12823159
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ranitidine at bedtime
Trial: 12022436
Drug: RRV-TV (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRV-TV (4 x 10(4) pfu/dose)
Trial: 1927942
Drug: Early patency
RxNorm normalized name: Tests for bile duct patency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early patency (both treatments)